Jan C Thomassen1, Matthias I Mueller2, Miguel A Alejandre Alcazar3, Ernst Rietschel2, Silke van Koningsbruggen-Rietschel2. 1. CF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Germany; Translational Experimental Pediatrics/Experimental Pulmonology, Children's Hospital, Faculty of Medicine, University of Cologne, Germany. Electronic address: Jan.thomassen@uk-koeln.de. 2. CF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Germany. 3. Translational Experimental Pediatrics/Experimental Pulmonology, Children's Hospital, Faculty of Medicine, University of Cologne, Germany.
Abstract
OBJECTIVE: To investigate the effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in patients with cystic fibrosis (CF) (Phe508del/Phe508del). METHODS: A standard oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test (IVGTT) were performed to investigate glucose metabolism and insulin secretion before and after 6-8weeks of treatment with Lumacaftor/Ivacaftor in 5 Phe508del-homozygous CF patients. The area under the curve (AUC) for glucose and insulin levels was calculated using the trapezoidal approximation. RESULTS: 5 participants were investigated. Treatment with Lumacaftor/Ivacaftor was followed by an improvement of the 2h glucose levels in 3 patients and worsening in 2 patients. Analysis of the time course of blood glucose levels during OGTT revealed an increase of the AUC in 3 of 5 patients. In response to IVGTT, acute insulin secretion improved in 2 patients and worsened in 3. CONCLUSION: The investigation could not demonstrate that treatment with Lumacaftor/Ivacaftor had a consistent impact on glucose tolerance and insulin secretion. Further adequately-powered studies examining glucose metabolism are needed to properly evaluate drug response in the endocrine pancreas and to test whether this treatment could eventually prevent the development of cystic fibrosis-related diabetes (CFRD).
OBJECTIVE: To investigate the effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in patients with cystic fibrosis (CF) (Phe508del/Phe508del). METHODS: A standard oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test (IVGTT) were performed to investigate glucose metabolism and insulin secretion before and after 6-8weeks of treatment with Lumacaftor/Ivacaftor in 5 Phe508del-homozygous CFpatients. The area under the curve (AUC) for glucose and insulin levels was calculated using the trapezoidal approximation. RESULTS: 5 participants were investigated. Treatment with Lumacaftor/Ivacaftor was followed by an improvement of the 2h glucose levels in 3 patients and worsening in 2 patients. Analysis of the time course of blood glucose levels during OGTT revealed an increase of the AUC in 3 of 5 patients. In response to IVGTT, acute insulin secretion improved in 2 patients and worsened in 3. CONCLUSION: The investigation could not demonstrate that treatment with Lumacaftor/Ivacaftor had a consistent impact on glucose tolerance and insulin secretion. Further adequately-powered studies examining glucose metabolism are needed to properly evaluate drug response in the endocrine pancreas and to test whether this treatment could eventually prevent the development of cystic fibrosis-related diabetes (CFRD).
Authors: Kevin J Scully; Peter Marchetti; Gregory S Sawicki; Ahmet Uluer; Manuela Cernadas; Rebecca E Cagnina; John C Kennedy; Melissa S Putman Journal: J Cyst Fibros Date: 2021-09-14 Impact factor: 5.482
Authors: Anh-Thu N Lam; Melis A Aksit; Briana Vecchio-Pagan; Celeste A Shelton; Derek L Osorio; Arianna F Anzmann; Loyal A Goff; David C Whitcomb; Scott M Blackman; Garry R Cutting Journal: J Clin Invest Date: 2020-01-02 Impact factor: 14.808
Authors: Angel Li; Tim Vigers; Laura Pyle; Edith Zemanick; Kristen Nadeau; Scott D Sagel; Christine L Chan Journal: J Cyst Fibros Date: 2018-08-10 Impact factor: 5.482
Authors: Yu-Chung Lin; Katherine Keenan; Jiafen Gong; Naim Panjwani; Julie Avolio; Fan Lin; Damien Adam; Paula Barrett; Stéphanie Bégin; Yves Berthiaume; Lara Bilodeau; Candice Bjornson; Janna Brusky; Caroline Burgess; Mark Chilvers; Raquel Consunji-Araneta; Guillaume Côté-Maurais; Andrea Dale; Christine Donnelly; Lori Fairservice; Katie Griffin; Natalie Henderson; Angela Hillaby; Daniel Hughes; Shaikh Iqbal; Jennifer Itterman; Mary Jackson; Emma Karlsen; Lorna Kosteniuk; Lynda Lazosky; Winnie Leung; Valerie Levesque; Émilie Maille; Dimas Mateos-Corral; Vanessa McMahon; Mays Merjaneh; Nancy Morrison; Michael Parkins; Jennifer Pike; April Price; Bradley S Quon; Joe Reisman; Clare Smith; Mary Jane Smith; Nathalie Vadeboncoeur; Danny Veniott; Terry Viczko; Pearce Wilcox; Richard van Wylick; Garry Cutting; Elizabeth Tullis; Felix Ratjen; Johanna M Rommens; Lei Sun; Melinda Solomon; Anne L Stephenson; Emmanuelle Brochiero; Scott Blackman; Harriet Corvol; Lisa J Strug Journal: Genet Med Date: 2021-01-26 Impact factor: 8.822
Authors: Amir Moheet; Daniel Beisang; Lin Zhang; Scott D Sagel; Jill M VanDalfsen; Sonya L Heltshe; Carla Frederick; Michelle Mann; Nicholas Antos; Joanne Billings; Steven M Rowe; Antoinette Moran Journal: J Cyst Fibros Date: 2020-09-08 Impact factor: 5.482